Une version française du cours de formation de CITI sur la division 5 est maintenant disponible; les institutions du C17 ont accès via l’inscription du C17 au N2

Remarque: Le C17 est membre N2 (Réseau des Réseau): les institutions du C17 ont accès à toutes les ressources d’enseignement et de formation N2, y compris la formation  CITI.

Le Cours de CITI sur la Division 5: Drogues destinées aux essais cliniques sur des sujets humains de Santé Canada a été traduit en français. Cette traduction a été possible grâce a l’aide financière généreusement offerte par le FRSQ. Vous pouvez y accéder en consultant le site Web de CITI: http://n2canada.us14.list-manage2.com/track/click?u=3701881b24851f487859ab8c8&id=b17362d464&e=33118d4f3d.

The Health Canada Division 5: Drugs for Clinical Trials Involving Human Subjects CITI Course has been translated into a French version. The FRQS has generously provided financial support to make this translation possible. It can now be accessed through the CITI website: http://n2canada.us14.list-manage2.com/track/click?u=3701881b24851f487859ab8c8&id=fc3e54cb50&e=33118d4f3d.


NAIT: KTE-C19 CAR T cell study open + May newsletter available

KTE-C19 now open: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia.  For more information see:  https://clinicaltrials.gov/ct2/show/NCT02625480


The May 2017 NAIT newsletter can be found HERE.  For more information on current and upcoming trials, please visit www.sickkids.ca/centres/gfcc/nait/index.html or send an email directly to nait.info@sickkids.ca

Solid Tumours: Dr. Daniel Morgenstern
Leukemia/Lymphoma: Dr. Jim Whitlock
CNS: Dr. Eric Bouffet
Patient Navigator: Karen Fung

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

JOB POSTING: Full Time Pediatric Hematologist/Oncologist Montreal Children’s Hospital (applications due June 1, 2017)

The Division of Pediatric Hematology/Oncology of the Montreal Children’s Hospital, McGill University Health Centre is seeking a full-time clinician for an academic appointment commensurate with qualifications and experience.  The individual would become part of an experienced and cohesive group caring for a broad range of patients within the specialty.  An interest in benign and malignant hematology as well as a record of clinical research would be an asset.  Candidates must have completed a fellowship in pediatric hematology/oncology and be board certified or eligible by the Royal College of Physicians and Surgeons of Canada or equivalent body.   Due to regulations of the Collège des Médecins du Québec candidates who completed their medical school training outside of North America, France, or Belgium will not be considered. In accordance with Canadian immigration requirements, priority will be given to Canadian citizens and permanent residents.  The MUHC is committed to providing equal employment opportunity to qualified individuals with diverse backgrounds and experiences including aboriginal people, visible minorities, and those with disabilities.

Interested individuals should send a letter of application, curriculum vitae, and the names and addresses of three referees by June 1, 2017 to:    

Dr. David Mitchell
Division Director, Pediatric Hematology/Oncology, Montreal Children’s Hospital
Email: david.mitchell@muhc.mcgill.ca

1001 Blvd Décarie, Room B05.2024, Montréal, Québec, Canada H4A 3J1

About the Division and Montreal Children’s Hospital

The MCH is a full service academic pediatric hospital that has had international influence in the care of children for over 110 years.  In 2015 it relocated to a brand new and very unique facility that is comprised of separate pediatric and adult hospitals, a Shriners Hospital, cancer centre, and basic research institute on one site.  All facilities are attached, facilitating collaboration between the pediatric and adult as well as the clinical and research sectors.  The division of hematology/oncology is located within the pediatric hospital with dedicated and adjacent inpatient and outpatient units.  The division sees 100 new oncology cases annually and a full range of benign hematology patients including 200 with sickle cell disease, is FACT certified for hematopoietic stem cell transplantation, and is very active in clinical, basic, and translational research.

About Montreal

Greater Montreal is a city of 4 million people with a very multicultural and cosmopolitan flavor.  French and English are the dominant languages and ability to communicate in both would be an asset.  It is renowned for its summer festivals, excellent selection of restaurants, proximity to world class skiing, and the opportunity for a high standard of living with the cost of real estate considerably lower than many other major metropolitan areas in Canada and United States.



West Coast Sarcoma Conference- December 1 & 2, 2017, Vancouver, BC- SAVE THE DATE & Mark your Calendars!

Dear Colleagues,

We are delighted to announce that the inaugural West Coast Sarcoma Conference will be taking place in Vancouver December 1-2, 2017.

WCSC will be unique in its inclusion of both pediatric and adult sarcoma specialists, with the objectives of ensuring best practices in sarcoma care and fostering collaboration across disciplines and geographic regions. We have succeeded in securing the participation of internationally renowned researchers and clinicians in the field of sarcoma.

We have put together an innovative program highlighting emerging techniques and current controversies in the diagnosis and management of sarcoma.

We look forward to welcoming you to Vancouver for the WCSC!

Save the date December 1 & 2, 2017 Vancouver, BC
Website will be open soon


  Drs. Karen Goddard, Andrea MacNeill, and Christine Simmons
Planning Committee Co-Chairs
West Coast Sarcoma Conference

Adolescents and Young Adults with Cancer System Report Available April 2017 (PDF and slide deck)

This report is available for download at: www.systemperformance.ca/reports/

The Canadian Partnership Against Cancer is pleased to share Adolescents and Young Adults with Cancer: A System Performance Report. This is the first time national data on the entire continuum of cancer control in adolescents and young adults have been reported.


Building on existing knowledge about cancer in this unique population, key findings include:

  • physical, emotional and practical needs during and after cancer treatment
  • challenges in oncofertility and resource availability to address fertility issues
  • gaps in current research funding and availability of clinical trials
  • more data required to better understand the needs of this group

We would like to acknowledge the Canadian Task Force on Adolescents and Young Adults with Cancer for their important contributions to this report.

Alex’s Lemonade Stand “Reach Grant” (preclinical focus, $250,000/2yrs) and “A Award” (early career support, $800,000/4yrs) applications due May 22, 2017

‘A’ Award Program Goals


  • To encourage the best and brightest early career independent researchers to build lifelong careers and become leaders in the field of pediatric cancer research.
  • To advance research that will lead to new treatments and cures impacting children with cancer.
  • Initial Awards are for $800,000 over 4 years (no more than $200,000 in any given year).
  • Funds must be granted to non-profit institutions or organizations operating in the United States or Canada. Researchers need not be U.S. citizens.

Reach Grants


  • To support important preclinical projects that are necessary to move a study from the pre-clinical arena into a clinical trial; selected late translational studies.
  • Preference will be given to those research projects which, if funded, will likely result in the initiation of a clinical trial two to three years from the start of the project.
  • Maximum of $125,000 in total costs may be requested per year.
  • Funds must be granted to non-profit institutions or organizations operating in the United States or Canada. Researchers need not be U.S. citizens.

Frustrated by regulations? Here’s your opportunity to provide feedback to Health Canada. Take this 10 question survey to help inform future directions of the Initiative to Streamline Clinical Trials (ISCT) Working Group

Initiative to Streamline Clinical Trials: Have The Guidelines Helped Cut Through the Red Tape?

Completing this 10-question survey will inform future directions of the Initiative to Streamline Clinical Trials (ISCT) Working Group, and provide information to be presented in discussions with Health Canada. We appreciate your support in taking a minute to complete the survey. Even if you are unfamiliar with the ISCT guidelines or have not implemented them, your responses will help shape future work on this initiative. The survey is anonymous and results will be aggregated. Click the link below to start the survey.
In 2011, the Canadian Cancer Research Alliance (CCRA) report on the State of Cancer Clinical Trials In Canada identified the magnitude of the threat to the conduct of oncology clinical trials. The report noted that with falling performance metrics, increasing complexity and workload, and an increasingly onerous regulatory environment, clinical trials were at risk, and observed that “Without clinical trials, the outcomes of cancer patients will not continue to improve”. One of the recommendations in the report recommended engaging with Health Canada and other key stakeholders to foster agreement in appropriate interpretations of the Health Canada Food and Drug Regulations and ICH Good Clinical Practice (GCP) guidelines.

In response, the Initiative to Streamline Clinical Trials (ISCT) Working Group was organized in 2012, and included members who are experts in clinical trial conduct across many therapeutic areas. The primary objective of the ISCT was to develop specific, pragmatic, and practical interpretations of current regulations, laws and guidelines, in order to facilitate, rather than limit, Canadian clinical trials, by expanding on recommendations such as those of the CCRA and OECD. The guidelines were finalized in February 2014 and are available at http://n2canada.ca/isct/.

Since the 2011 CCRA report, the ISCT Guidelines has been one of many initiatives underway nationally to address threats to the clinical trial enterprise. While results are promising, understanding of the current environment as well as the implementation and impact of the ISCT Guidelines by academic Investigators, Institutions, and Sponsors is needed to determine future actions required.

SAVE-THE-DATE: C17 “Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology” educational workshop (Saturday, 4 November 2017)

C17 “Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology educational workshop being held on Saturday, 4 November 2017 in Vancouver, BC. The workshop is in response to the C17 DVL needs assessment that was completed last year as we expanded the C17 DVL network across Canada from 8 to 11 sites. While many investigators and research staff have had experience or education in early phase trials, here was a need identified to provide education and mentorship to research staff conducting early phase trials. With the development of pediatric precision medicine trials in Canada, the need will be even greater.

The workshop is a full day, pre-session workshop at the CCRA Canadian Cancer Research Conference. We hope that most attendees at our workshop will take the opportunity to attend the full conference as well.

The workshop will be designed to educate investigators on traditional models of early phase trials as well as newer approaches to drug development. We will also cover regulatory, ethical, advocacy and access aspects of early phase trials. The workshop will proved education, discussions, panels and time for questions.

Our goal will be to help provide some funding to C17 DVL participating centres to allow investigators and senior research staff to attend.


More details will be circulated once available.


STUDY SPOTLIGHT: Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia

This multi-center open label clinical trial aims to identify predictors of low antibody titers to vaccine antigens in children with ALL who completed chemotherapy in the prior 6 months, and to determine the immunogenicity and safety of diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b (DTaP-IPV-Hib) and 13-valent pneumococcal conjugate vaccine (PCV13) booster immunization administered 6 months post-chemotherapy, followed by 23-valent pneumococcal polysaccharide vaccination (PPV23) 2 months later. The results will support the development of clinical practice guidelines for this population.

Official Title: Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study
Cooperative Group: Canadian Immunization Research Network (CIRN)
Study ID: NCT02447718, CIRN SI02
For more information see, https://clinicaltrials.gov/ct2/show/NCT02447718 and http://cirnetwork.ca/research-study/vaccinating-after-chemotherapy-or-hematopoietic-stem-cell-transplant/